EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Registration of health products for human use: Niger Republic case (from January 2018 to December 2020)

Mahaman Rabiou MAMANE IBRAHIM, Ousmane ABDOULAYE, Rakia ABDOU BAGOUGOU, Fatima GUIET MATI, Mahamadou OUDOU MOSSI MAIGA, Hamidou HAROUNA, Mahaman Laouali HAROUNA AMADOU, Kassoum JATAOU BAHARI, Nouhou HAMA AGHALI, Habsatou MINDAOUDOU, Bachir ILLO, Barira DAN NOUHOU

International Journal of Drug Regulatory Affairs · 2022

DOI: 10.22270/ijdra.v10i2.526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, 2022. Verfasst von Mahaman Rabiou MAMANE IBRAHIM und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our study aims to make a nomenclature of the pharmaceutical products having received an authorization of sale on the market (MA) in Niger Republic and to describe the profiles of the various applicant laboratories and or manufacturers. We had conducted a retrospective and descriptive study on new applications for registration of health products for human use examined in first intention only by the National Commission for Health Products Approval (NCHPA) from January 2018 to December 2020. Material and methods: Over this period, 7 sessions of the NCHPA were held, including 3 in 2018, 2 in 2019, and 2 in 2020. In total, 951 dossiers for registration were reviewed in first intention.

Results

It was found that the majority of applicant laboratories (37.22%) as well as manufacturer laboratories (40.38%) were from India. The most represented therapeutic class was antibiotics (21.35%) followed by antimalarial (9.67%). However, the main route of administration was oral (79.28%) with a predominance of tablets (52.47%). Our study had also noted that only 10.10% of the dossiers have been accepted against 86.75% postponed due to lack of required information. Summary ad conclusion: The national drug nomenclature remains the main document guiding the prescription and dispensing of products with a valid market authorization in the country. This is why all the actors in pharmaceutical logistics must have at hand all the information on the products approved in Niger.

Zitieren

APA

IBRAHIM, M. R. M., ABDOULAYE, O., BAGOUGOU, R. A., MATI, F. G., MAIGA, M. O. M., HAROUNA, H., AMADOU, M. L. H., BAHARI, K. J., AGHALI, N. H., MINDAOUDOU, H., ILLO, B., & NOUHOU, B. D. (2022). Registration of health products for human use: Niger Republic case (from January 2018 to December 2020). International Journal of Drug Regulatory Affairs. https://doi.org/10.22270/ijdra.v10i2.526

Vancouver

IBRAHIM MRM, ABDOULAYE O, BAGOUGOU RA, MATI FG, MAIGA MOM, HAROUNA H, et al. Registration of health products for human use: Niger Republic case (from January 2018 to December 2020). International Journal of Drug Regulatory Affairs. 2022. doi:10.22270/ijdra.v10i2.526

BibTeX
@article{IBRAHIM2022,
  author = {IBRAHIM, Mahaman Rabiou MAMANE and ABDOULAYE, Ousmane and BAGOUGOU, Rakia ABDOU and MATI, Fatima GUIET and MAIGA, Mahamadou OUDOU MOSSI and HAROUNA, Hamidou and AMADOU, Mahaman Laouali HAROUNA and BAHARI, Kassoum JATAOU and AGHALI, Nouhou HAMA and MINDAOUDOU, Habsatou and ILLO, Bachir and NOUHOU, Barira DAN},
  title = {Registration of health products for human use: Niger Republic case (from January 2018 to December 2020)},
  journal = {International Journal of Drug Regulatory Affairs},
  year = {2022},
  doi = {10.22270/ijdra.v10i2.526}
}
Kostenlos starten →